Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

21 Oct 2016
Change (% chg)

-0.50p (-0.37%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for VEC.L


Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) -... (more)


Beta: 0.76
Market Cap(Mil.): £913.23
Shares Outstanding(Mil.): 677.47
Dividend: --
Yield (%): --


  VEC.L Industry Sector
P/E (TTM): 117.94 36.48 36.35
EPS (TTM): 0.01 -- --
ROI: 1.98 14.43 13.88
ROE: 2.18 15.21 14.79

Drugmaker Vectura raises revenue outlook on strong trading

Sept 7 Drugmaker Vectura Group Plc said it raised its revenue expectations for the nine months to Dec. 31 following strong trading to the end of August.

07 Sep 2016

Vectura's asthma therapy misses primary endpoint in final stage trial

Aug 30 Respiratory drug specialist Vectura Group Plc said its asthma therapy Flutiform had not met the primary endpoint in a phase III trial carried out by its European partner Mundipharma.

30 Aug 2016

BRIEF-Vectura initiates legal proceedings against GSK in the U.S.

* Vectura initiates legal proceedings against GlaxoSmithKline Plc (GSK)

27 Jul 2016

BRIEF-HBM Healthcare Investments: merger of Skyepharma and Vectura effective

* Recommended all share merger of Skyepharma and Vectura becomes effective

10 Jun 2016

BRIEF-Vectura FY core earnings rise 43 pct

* EBITDA(1) up 43% to £23.2m (2014/15: £16.2m) Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

26 May 2016

BRIEF-Vectura & Propeller Health announce collaboration

* Vectura and propeller health announce collaboration to develop digitally-connected inhalers to address chronic respiratory diseases Source text for Eikon: Further company coverage:

24 May 2016

BRIEF-Vectura Group says CMA not to investigate Vectura-Skyepharma merger

* CMA has confirmed that proposed recommended all share merger of Vectura and Skyepharma does not qualify for investigation

16 May 2016

BRIEF-UK's CMA says no relevant merger situation in Vectura-Skyepharma deal

* UK's CMA says decided that a relevant merger situation has not been created in anticipated acquisition by Vectura Group Plc of Skyepharma Plc Source text for Eikon:

16 May 2016

Earnings vs. Estimates